SCHEMBL795284

SCHEMBL795284

Cc1ccc(B2OC(C)(C)C(C)(C)O2)c2cccnc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.43
KMT2A Q03164 5/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
HTT P42858 5/20 0.41
PSMD14 O00487 2/20 0.41
COPS5 Q92905 2/20 0.41
SLC6A2 P23975 1/20 0.41
L3MBTL1 Q9Y468 4/20 0.41
NPC1 O15118 2/20 0.41
HSP90AA1 P07900 2/20 0.41
HTR1A P08908 1/20 0.39
ADRA1D P25100 1/20 0.39
ADRA1A P35348 1/20 0.39
ADRA1B P35368 1/20 0.39
CCR1 P32246 2/20 0.38
CCR8 P51685 2/20 0.38
MAPT P10636 4/20 0.36
LMNA P02545 2/20 0.36
USP2 O75604 1/20 0.36
RECQL P46063 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26922460 0.84 KDM4E (0.44) HTTPSMD14COPS5SLC6A2L3MBTL1
SCHEMBL29734917 0.84 KDM4E (0.44) HTTPSMD14COPS5SLC6A2L3MBTL1
SCHEMBL26920675 0.84 KDM4E (0.41) MEN1KMT2ASMN1; SMN2HTTSLC6A2
SCHEMBL29778034 0.81 MEN1 (0.38) MEN1KMT2APSMD14COPS5L3MBTL1
SCHEMBL12600437 0.81 COMT (0.49) MEN1KMT2ASMN1; SMN2HTTL3MBTL1
SCHEMBL26921299 0.80 L3MBTL1 (0.33) L3MBTL1NPC1HSP90AA1KDM4EMPI
SCHEMBL22127690 0.80 LRRK2 (0.36) L3MBTL1NPC1HSP90AA1
SCHEMBL26923229 0.79 PDK2 (0.38) L3MBTL1NPC1HSP90AA1
SCHEMBL26921011 0.79 CYP2C19 (0.36) HTTSLC6A2L3MBTL1NPC1HSP90AA1
SCHEMBL26922130 0.79 ALDH1A1 (0.42) MEN1KMT2ASMN1; SMN2HTTL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250214977-A1 STAT6 INHIBITORS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2025-07-03 US disclosed
EP-2616071-A2 FATTY ACID SYNTHASE INHIBITORS GlaxoSmithKline Intellectual Property Development Limited (GB) 2013-07-24 EP disclosed
US-20130172384-A1 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED 2013-07-04 US disclosed
WO-2012037299-A2 FATTY ACID SYNTHASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2012-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250214977-A1 STAT6 INHIBITORS AND USES THEREOF STAT6, STAT5B, STAT5A MEN1 2738/4885KMT2A 296/4885SMN1; SMN2 4785/4885
US-20130172384-A1 FATTY ACID SYNTHASE INHIBITORS FASN, FADS1, FADS2 MEN1 4467/4885KMT2A 2500/4885SMN1; SMN2 4821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.